Skip Navigation
Explore our COVID-19 Resources and Updates
CHS blue logo square
Home > Our Work > All Publications > 2008


Our publications keep professionals informed on the most important developments and issues in health security and biosecurity.

Find an article or report by keywords:

Find an article or report or see all by area, author, or year:


Cost/Success Projections for U.S. Biodefense Countermeasure Development

Jason Matheny, Michael Mair, Bradley Smith
Date posted:
September 01, 2008
Publication type:

Nat Biotechnol 2008;26(9):981-983

Nature Publishing Group
On publisher's site
See also:

Full article on publisher's site: HTML • PDF


To the Editor:

To protect civilians against biological weapons and bioterrorism, the US Department of Health and Human Services (HHS) has developed a list of essential medical countermeasure requirements. We performed a survey of candidate biodefense countermeasures in development and estimated their future clinical development costs, based on historical drug and vaccine development data. The cost of supporting existing candidates through clinical development is estimated to be $4.1 billion over the next seven years, with costs of $817 million in fiscal year 2009, alone. Given the high failure rate of biopharmaceutical development, the probability of developing approved products from the existing pipeline is between 12% and 85% per HHS requirement. To increase the probability to 90%, two to nine additional candidates will be needed per requirement, at a total seven-year clinical development cost of $14.0 billion. To date, the primary government program tasked with supporting clinical development of medical countermeasures has received only $201 million.

Full article on publisher's site: HTML • PDF



Our Mission

To protect people’s health from epidemics and disasters and ensure that communities are resilient to major challenges.